Equibles does not estimate personal net worth.
Get an email with a short summary when Bio-Rad Laboratories, Inc. publishes a filing, an earnings call transcript or a press release.
Get BIO alertsRoop Lakkaraju is recorded as CFO at Bio-Rad Laboratories, Inc. (BIO). The proxy statement of Bio-Rad Laboratories, Inc. reports total compensation of $2,990,738 for Roop Lakkaraju in fiscal 2025, including a base salary of $629,100. Disclosed compensation is on record for 2 fiscal years. Roop Lakkaraju has spoken on 8 earnings calls and 2 other investor events across 1 company, most recently for Bio-Rad Laboratories, Inc. on September 9, 2026. Bio-Rad Laboratories, Inc. is classified in the Medical Devices industry within the Healthcare sector. Other leadership on record at Bio-Rad Laboratories, Inc. includes Norman Schwartz (CEO, CFO and Board Member), Roop K. Lakkaraju (CFO and Chief Accounting Officer), Jonathan DiVincenzo (COO) and 7 others.
“First of all, Evan, thanks for having us and appreciate, uh, the opportunity to participate at the conference. Uh, it's been very good for us. In terms of the second quarter, second quarter was on a year-over-year basis, fairly similar to the second quarter of last year.”
“First of all, Evan, thanks for having us and appreciate, uh, the opportunity to participate at the conference. Uh, it's been very good for us. In terms of the second quarter, second quarter was on a year-over-year basis, fairly similar to the second quarter of last year.”
“I'd like to start with a review of the second quarter of 2026 results, then move to guidance. Overall, net sales for the second quarter of 2026 were approximately $651 million on a reported basis versus $652 million in Q2 of 2025.”
“I'd like to start with a review of the first quarter of 2026 results. Net sales for the first quarter of 2026 were approximately $592 million, which represents a 1.1% increase on a reported basis versus $585 million in Q1 of 2025.”
“I'd like to start with a review of the fourth quarter and full year 2025 results. Net sales for the fourth quarter of 2025 were approximately $693 million, which represents a 3.9% increase on a reported basis versus $668 million in Q4 of 2024.”
Medical Devices · Healthcare
CFO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Bio-Rad Laboratories, Inc. (BIO) | CFO | $629,100 | $2,990,738 |
| 2024 | Bio-Rad Laboratories, Inc. (BIO) | CFO | $426,923 | $3,775,075 |
